StageTake Private | Alive
Radius Health is a biopharmaceutical company focused on developing new therapeutics to treat osteoporosis and other women's health conditions. It is committed to the development of therapeutics for the osteoporosis market. The company's lead product candidate, BA058-SC, is in effect to reduce the risk of complications associated with osteoporosis, such as fractures and has a transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. The company was founded in 2003 and is based in Boston, Massachusetts.
Missing: Radius's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Radius's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Radius
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Radius is included in 2 Expert Collections, including Women's Health & Wellness.
Women's Health & Wellness
Startups focused on providing products and services catering to women's health and wellbeing.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Radius has filed 48 patents.
The 3 most popular patent topics include:
- G protein coupled receptors
- Rare diseases
- Peptide hormones
Latest Radius News
Mar 20, 2023
LONDON--(BUSINESS WIRE)--Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingd
Radius Frequently Asked Questions (FAQ)
When was Radius founded?
Radius was founded in 2003.
Where is Radius's headquarters?
Radius's headquarters is located at 22 Boston Wharf Rd, Boston.
What is Radius's latest funding round?
Radius's latest funding round is Take Private.
How much did Radius raise?
Radius raised a total of $224.5M.
Who are the investors of Radius?
Investors of Radius include Patient Square Capital, Gurnet Point Capital, MPM Capital, Bain Capital Public Equity, BB Biotech Ventures and 17 more.
Who are Radius's competitors?
Competitors of Radius include AVEO Oncology, Zosano Pharma, Aquinox Pharmaceuticals, Aegerion Pharmaceuticals, Athenex and 12 more.
Compare Radius to Competitors
Renovo provides drug discovery and development for scar prevention and reduction.
MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates.
Alvine Pharmaceuticals is a clinical-stage, specialty biopharmaceutical company focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. ALV003 is an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP). ALV003 targets gluten and degrades it into small fragments, which, in vitro, diminishes its immunogenicity. ALV003 is being developed as a potential treatment for celiac disease patients in conjunction with a gluten-free diet and is currently in phase 2 clinical development.
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
Verus Pharmaceuticals is developing products treating asthma
Altheos, Inc. is an early-stage biopharmaceutical company focused on the identification and development of promising well-differentiated novel small molecule drugs for unmet medical needs. Altheos, Inc. was co-founded in 2009 by two experienced pharmaceutical drug development executives and entrepreneurs, Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. The company is headquartered in South San Francisco, California.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.